Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Hip examination

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44339   clinical trials with a EudraCT protocol, of which   7369   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    98 result(s) found for: Hip examination. Displaying page 5 of 5.
    « Previous 1  2  3  4  5 
    EudraCT Number: 2012-005114-20 Sponsor Protocol Number: GS-US-292-0109 Start Date*: 2013-07-03
    Sponsor Name:Gilead Sciences, Inc.
    Full Title: A Phase 3, Open-Label Study to Evaluate Switching from a TDF-Containing Combination Regimen to a TAF-Containing Combination Single Tablet Regimen (STR) in Virologically-Suppressed, HIV-1 Positive S...
    Medical condition: Human Immunodeficiency Virus (HIV-1) Infection
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004862 10068341 HIV-1 infection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) SE (Completed) DE (Completed) GB (Completed) IT (Completed) AT (Completed) NL (Completed) ES (Completed) DK (Completed) PT (Completed)
    Trial results: View results
    EudraCT Number: 2011-000180-28 Sponsor Protocol Number: GWMD09126 Start Date*: 2011-07-12
    Sponsor Name:GW Pharma Ltd
    Full Title: A randomised, double-blind, placebo-controlled parallel group, pilot study of 40:1 ratio of formulated GWP42003 : GWP42004 in the treatment of iatrogenic weight gain and dyslipidaemia associated wi...
    Medical condition: Iatrogenic weight gain and dyslipidaemia associated with treatment using antipsychotic medication
    Disease: Version SOC Term Classification Code Term Level
    14.1 10027433 - Metabolism and nutrition disorders 10058110 Dyslipidemia LLT
    14.1 10022891 - Investigations 10047896 Weight gain LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2018-001516-30 Sponsor Protocol Number: GDX-44-007 Start Date*: Information not available in EudraCT
    Sponsor Name:GUERBET
    Full Title: Pharmacokinetics, safety and efficacy of a new gadolinium-based contrast agent, gadopiclenol, in pediatric patients from 2 to 17 years of ageundergoing contrast-enhanced MRI.
    Medical condition: Pediatric subjects from 2 to 17 years old scheduled to undergo routine gadolinium contrast enhanced Magnetic Resonance Imaging of Central Nervous System
    Disease: Version SOC Term Classification Code Term Level
    21.1 10022891 - Investigations 10029817 Nuclear magnetic resonance imaging brain PT
    21.1 10022891 - Investigations 10072232 Nuclear magnetic resonance imaging spinal PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: SK (Ongoing) PL (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2007-000123-18 Sponsor Protocol Number: NN304 - 1833 Start Date*: 2007-08-03
    Sponsor Name:Novo Nordisk A/S
    Full Title: A randomised, controlled, parallel, open-labelled, multinational, trial comparing the efficacy and safety of step-wise addition of insulin aspart according to the largest meals (Basic Basal Plus re...
    Medical condition: type 2 diabetes
    Disease: Version SOC Term Classification Code Term Level
    9.1 10045242 Type II diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) GB (Completed) DK (Completed) ES (Completed) FI (Completed) FR (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2017-004581-10 Sponsor Protocol Number: CL2-201086-002 Start Date*: 2018-09-04
    Sponsor Name:Institut de Recherches Internationales Servier
    Full Title: Efficacy and safety of 3 doses of S201086/GLPG1972 administered orally once daily in patients with knee osteoarthritis. A 52-week international, multi-regional, multi-center, randomized, double-bli...
    Medical condition: Osteoarthritis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10028395 - Musculoskeletal and connective tissue disorders 10031161 Osteoarthritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) HU (Completed) DK (Completed) PL (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2013-004137-32 Sponsor Protocol Number: 111-202 Start Date*: 2014-04-03
    Sponsor Name:BioMarin Pharmaceutical Inc.
    Full Title: A Phase 2, Open-label, Sequential Cohort Dose-escalation Study of BMN 111 in Children with Achondroplasia
    Medical condition: achondroplasia
    Disease: Version SOC Term Classification Code Term Level
    19.1 100000004850 10000452 Achondroplasia LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2006-003475-13 Sponsor Protocol Number: A1281148 Start Date*: 2006-12-08
    Sponsor Name:Pfizer Pharma GmbH
    Full Title: A SIXTEEN-WEEK, MULTI-CENTER, OPEN-LABEL STUDY EVALUATING THE SAFETY, TOLERABILITY, AND EFFICACY OF SWITCHING FROM QUETIAPINE TO ZIPRASIDONE IN SUBJECTS DIAGNOSED WITH SCHIZOPHRENIA OR SCHIZOAFFECT...
    Medical condition: Schizophrenia and Schizoaffective Disorder
    Disease: Version SOC Term Classification Code Term Level
    8.1 10039635 Schizophrenia schizoaffective LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2017-003803-22 Sponsor Protocol Number: AG348-C-007 Start Date*: 2018-06-27
    Sponsor Name:Agios Pharmaceuticals, Inc.
    Full Title: An Open-Label Study to Evaluate the Efficacy and Safety of AG-348 in Regularly Transfused Adult Subjects With Pyruvate Kinase (PK) Deficiency
    Medical condition: Pyruvate Kinase Deficiency
    Disease: Version SOC Term Classification Code Term Level
    21.1 10010331 - Congenital, familial and genetic disorders 10037682 Pyruvate kinase deficiency anaemia PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Completed) DK (Completed) GB (Completed) IE (Completed) IT (Completed) ES (Prematurely Ended) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2017-001185-20 Sponsor Protocol Number: 167700-005CL Start Date*: 2017-12-05
    Sponsor Name:Proximagen Limited
    Full Title: A Randomized, Double Dummy, Parallel Arm, Placebo and Active Controlled, Double Blind, Study of the Safety and Efficacy of PRX167700 as Monotherapy in Adults with Moderate to Severe Knee Pain Due ...
    Medical condition: Moderate to Severe Knee Pain Due to Osteoarthritis in subjects who are Inappropriate for Oral Non steroidal Anti inflammatory Therapy
    Disease: Version SOC Term Classification Code Term Level
    20.0 10028395 - Musculoskeletal and connective tissue disorders 10031161 Osteoarthritis PT
    20.0 10028395 - Musculoskeletal and connective tissue disorders 10023476 Knee osteoarthritis LLT
    20.0 10028395 - Musculoskeletal and connective tissue disorders 10031165 Osteoarthritis knee LLT
    20.0 10028395 - Musculoskeletal and connective tissue disorders 10024776 Localised osteoarthritis LLT
    20.0 10028395 - Musculoskeletal and connective tissue disorders 10031166 Osteoarthritis knees LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2010-018638-29 Sponsor Protocol Number: LUC10-001 Start Date*: 2012-04-23
    Sponsor Name:Centre du Cancer des Cliniques Universitaires Saint-Luc
    Full Title: Phase I/II study of peptide vaccination associated with GM-CT-01, a galactomannan oligomer that inhibits galestin-3, in patients with advanced metastatic melanoma
    Medical condition: Metastatic melanoma
    Disease: Version SOC Term Classification Code Term Level
    14.0 10042613 - Surgical and medical procedures 10025651 Malignant melanoma excision LLT
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027150 Melanoma malignant LLT
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10042550 Superficial spreading melanoma stage II PT
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029488 Nodular melanoma LLT
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025662 Malignant melanoma of skin of scalp and neck LLT
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10040891 Skin melanoma LLT
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10056768 Malignant melanoma of skin of lower limb, incl hip LLT
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10048434 Melanoma malignant aggravated LLT
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10042548 Superficial spreading melanoma in situ LLT
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025652 Malignant melanoma in situ PT
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10056792 Malignant melanoma of skin of trunk, excl scrotum LLT
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025667 Malignant melanoma site/stage unspecified LLT
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10042553 Superficial spreading melanoma stage unspecified PT
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027152 Melanoma of skin (malignant) LLT
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025660 Malignant melanoma of skin of lower limb, including hip LLT
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025653 Malignant melanoma of other specified sites of skin LLT
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10024226 Lentigo melanoma LLT
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025659 Malignant melanoma of skin of lip LLT
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025650 Malignant melanoma PT
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025665 Malignant melanoma of skin stage unspecified LLT
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025661 Malignant melanoma of skin of other and unspecified parts of face LLT
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10056769 Malignant melanoma of skin of upper limb, incl shoulder LLT
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066600 Melanoma recurrent PT
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10042547 Superficial spreading melanoma LLT
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025657 Malignant melanoma of skin of ear and external auricular canal LLT
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027155 Melanoma skin LLT
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025668 Malignant melanoma stage I PT
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027148 Melanoma in situ LLT
    14.0 10042613 - Surgical and medical procedures 10047981 Wide excision of melanoma LLT
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10053571 Melanoma LLT
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025670 Malignant melanoma stage III PT
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025663 Malignant melanoma of skin of trunk, except scrotum LLT
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027481 Metastatic melanoma LLT
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025656 Malignant melanoma of skin of ear and external auditory canal LLT
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027154 Melanoma of trunk and head LLT
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10042549 Superficial spreading melanoma stage I PT
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10042552 Superficial spreading melanoma stage IV PT
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025671 Malignant melanoma stage IV PT
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027149 Melanoma limited to extremity LLT
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025664 Malignant melanoma of skin of upper limb, including shoulder LLT
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027480 Metastatic malignant melanoma PT
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025655 Malignant melanoma of skin LLT
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025669 Malignant melanoma stage II PT
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027153 Melanoma of skin, site unspecified LLT
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10042551 Superficial spreading melanoma stage III PT
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027156 Skin melanomas (excl ocular) HLT
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10056767 Malignant melanoma of skin of eyelid, incl canthus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2021-006038-37 Sponsor Protocol Number: TAK-573-1501 Start Date*: 2022-10-11
    Sponsor Name:Takeda Development Center Americas, Inc.
    Full Title: A Phase 1/2 Open-label Study to Investigate the Safety and Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of Modakafusp Alfa (TAK-573) as a Single Agent in Patients With Relapsed Refr...
    Medical condition: Relapsed/Refractory Multiple Myeloma
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10028228 Multiple myeloma LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NO (Completed) DE (Prematurely Ended) FR (Completed) IE (Completed) ES (Completed) GR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2014-004805-34 Sponsor Protocol Number: TDU13828-ACT13830 Start Date*: 2015-04-02
    Sponsor Name:Sanofi-aventis Research & Development
    Full Title: A Two Part Protocol Using Double Blind Placebo Control to Assess the Safety, Tolerability, and Pharmacokinetics of Single Escalating Intra-articular Doses Followed by Assessment of Efficacy, Safety...
    Medical condition: Osteoarthritis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10028395 - Musculoskeletal and connective tissue disorders 10031161 Osteoarthritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2018-002217-35 Sponsor Protocol Number: AG348-C-010 Start Date*: 2018-11-20
    Sponsor Name:Agios Pharmaceuticals, Inc.
    Full Title: A Phase 2, Open-Label, Multicenter Study to Determine the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of AG-348 in Adult Subjects With Non-Transfusion-Dependent Thalassemia
    Medical condition: Non-Transfusion-Dependent Thalassemia
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10074356 Non-transfusion dependent thalassemia LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2008-001744-39 Sponsor Protocol Number: BC20963 Start Date*: 2008-10-21
    Sponsor Name:F.Hoffmann-La Roche Ltd
    Full Title: A multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy, safety and tolerability of taspoglutide (RO5073031) compared to placebo, in patients with type 2 diabetes m...
    Medical condition: Type 2 diabetes mellitus
    Disease: Version SOC Term Classification Code Term Level
    9.1 10012601 Diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2018-003459-39 Sponsor Protocol Number: AG348-C-011 Start Date*: 2019-04-10
    Sponsor Name:Agios Pharmaceuticals, Inc.
    Full Title: An Open-Label, Multicenter, Extension Study of AG-348 in Adult Subjects with Pyruvate Kinase Deficiency Previously Enrolled in AG-348 Studies
    Medical condition: Pyruvate Kinase Deficiency Haemolytic anaemia
    Disease: Version SOC Term Classification Code Term Level
    21.1 10010331 - Congenital, familial and genetic disorders 10037682 Pyruvate kinase deficiency anaemia PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DK (Completed) GB (GB - no longer in EU/EEA) ES (Ongoing) FR (Completed) IE (Completed) NL (Completed) DE (Completed) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-005147-40 Sponsor Protocol Number: 201636 Start Date*: 2015-05-07
    Sponsor Name:ViiV Healthcare, S.L.
    Full Title: A Phase III, randomized, multicenter, parallel-group, noninferiority study evaluating the efficacy, safety, and tolerability of switching to dolutegravir plus rilpivirine from current INI-, NNRTI-,...
    Medical condition: Human immunodeficiency virus type 1 (HIV-1)
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004862 10003582 Asymptomatic human immunodeficiency virus type I infection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) DE (Completed) NL (Completed) BE (Completed) GB (GB - no longer in EU/EEA) IT (Completed)
    Trial results: View results
    EudraCT Number: 2019-004941-34 Sponsor Protocol Number: GFT505B-319-1 Start Date*: 2020-10-09
    Sponsor Name:IPSEN Pharma SAS
    Full Title: A Double-blind Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients with Primary Biliary Cholangitis with Ina...
    Medical condition: Primary Biliary Cholangitis
    Disease: Version SOC Term Classification Code Term Level
    21.0 10019805 - Hepatobiliary disorders 10034176 PBC LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Trial now transitioned) DE (Trial now transitioned) FR (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-003177-58 Sponsor Protocol Number: SPIOMET4HEALTH Start Date*: 2022-05-12
    Sponsor Name:Fundació Sant Joan de Déu (FSJD)
    Full Title: A Phase II, randomised, multi-centric, multi-national clinical trial to evaluate the efficacy, tolerability, and safety of a fixed dose combination of Spironolactone, Pioglitazone & Metformin (SPIO...
    Medical condition: Polycystic Ovary Syndrome (PCOS)
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004872 10065161 Polycystic ovarian syndrome LLT
    Population Age: Adolescents, Under 18, Adults Gender: Female
    Trial protocol: AT (Trial now transitioned) NO (Trial now transitioned) IT (Trial now transitioned) DK (Trial now transitioned) ES (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  5 
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun Jun 01 19:51:50 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA